OncoMatch/Clinical Trials/NCT06993844
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Is NCT06993844 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including ETX-636 dose escalation and ETX-636 dose escalation in combination with fulvestrant for advanced solid tumors.
Treatment: ETX-636 dose escalation · ETX-636 dose escalation in combination with fulvestrant · ETX-636 dose expansion in combination with fulvestrant — Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Breast Carcinoma
Biomarker criteria
Required: PIK3CA activating mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received:
has progressed on or after at least one available therapy
Must have received: CDK4/6 inhibitor
must have received at least 1 prior CDK4/6 inhibitor
Must have received: anti-estrogen therapy
must have received at least 1 prior anti-estrogen therapy
Cannot have received: local or systemic anticancer therapy or investigational anticancer agent
Has received treatment with any local or systemic anticancer therapy or investigational anticancer agent within 14 days prior to start of treatment
Cannot have received: radiotherapy
Has had radiotherapy outside the target tumor lesions within 14 days prior to start of treatment
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- Yale University, Yale Cancer Center · New Haven, Connecticut
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify